As we reported in Wyatt’s weekly COVID-19 Newsletter on July 2, 2020, the U.S. Department of Health & Human Services (HHS), announced on June 29, 2020 an agreement to secure more than 500,000 treatment courses of the drug remdesivir for the United States from Gilead Sciences through September.  As Gilead’s donated supply of remdesivir has been exhausted, U.S. hospitals will be required to purchase the drug at the Wholesale Acquisition Cost (WAC) of approximately $3,200 per treatment course.  The delivery of the purchased remdesivir will be streamlined, shipping directly from AmerisourceBergen to hospitals about every two weeks.

However, a hospital’s bi-weekly purchase will be limited to the amount of remdesivir determined to be its fair share based on current COVID-19 hospitalizations reported by the hospital.  The American Hospital Association (AHA) issued a Special Bulletin last week reminding hospitals to submit their COVID-19 patient data through the U.S. Healthcare COVID-19 TeleTracking Portal each Monday by 8 pm, every two weeks, beginning today, July 6, 2020.  The AHA bulletin further states: “All hospitals should report at least the six data fields for COVID-19 admissions and ICU numbers into TeleTracking, even if they are using another reporting mechanism (e.g., National Healthcare Safety Network, or state reporting) for daily reporting.”

For additional information on how to submit data see the AHA’s Special Bulletin of May 11, 2020.

For additional information, contact Kathie McDonald-McClure, Partner, Louisville Office, Phone (502) 562-7526, Email kmcclure@wyattfirm.com. For more information about Wyatt’s Health Care Legal Service Team and its members, click here.